Saturday 17 October 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
In the quarter to June 2026, EPS fell 5.63% and free cash flow fell 5.96%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
26.73
0.78
−2.84%
Follow IMVT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 9.57 | 8.34 | 6.68 | 3.15 | 14.05 | 23.88 | 12.72 | 22.79 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | 16.64 | 53.75 | 50.32 | 17.90 | 44.85 | 45.58 | 27.69 | 45.42 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 17 | 42 | 68 | 124 | 164 | 207 | 362 | 315 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | 0 | (29) | (66) | (108) | (157) | (211) | (259) | (413) | (505) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (29) | (66) | (107) | (157) | (211) | (259) | (414) | (506) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (1.29) | (1.54) | (1.22) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) | |||||
| Cash flow | — | 0.00 | (1.29) | (1.24) | (0.95) | (0.97) | (1.53) | (1.55) | (2.48) | (2.23) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | 0.00 | (1.29) | (1.24) | (0.95) | (0.97) | (1.53) | (1.55) | (2.48) | (2.23) | |||||
| Book value | — | 0.00 | 0.33 | 2.18 | 4.46 | 4.28 | 2.95 | 4.47 | 4.67 | 4.67 | |||||
| Shares, m | — | 14 | 22 | 43 | 88 | 110 | 123 | 138 | 152 | 182 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (29) | (53) | (83) | (106) | (188) | (214) | (376) | (407) | ||||
| Capex | — | — | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | (29) | (53) | (84) | (106) | (188) | (215) | (377) | (407) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | 6 | 94 | 390 | 468 | 361 | 617 | 699 | 844 | ||||
| Total debt | — | 0 | — | 3 | 3 | 3 | 2 | — | — | — | |||||
| Net debt | — | 0 | (7) | (101) | (400) | (494) | (377) | (635) | (714) | (902) | |||||
| Shareholders’ equity | — | 0 | 7 | 94 | 391 | 470 | 362 | 618 | 707 | 853 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (0.01) | (401.87) | (107.76) | (41.17) | (33.78) | (45.79) | (48.37) | (57.37) | (58.34) | ||||
| ROIC | — | 0.00 | (5,018.54) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | (0.01) | (776.77) | (130.93) | (44.25) | (36.39) | (50.69) | (52.91) | (62.46) | (64.82) | |||||
Negative figures in brackets.
Charts ten years each
Immunovant, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR | $6.2B | — (loss-making) | — | — | n/m | +64.67% (above 0%: growing) | — | 0.00% | Compare |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.1B | — (loss-making) | — (loss-making) | +46.91% (above 0%: growing) | n/m | +60.74% (above 0%: growing) | 87.47% | (68.14%) | Compare |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 29.5× | 54.7× | +33.73% (above 0%: growing) | +868.00% (above 0%: growing) | +35.53% (above 0%: growing) | 94.95% | 13.49% | Compare |
| IMVT Immunovant, Inc. | $5.7B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | |
| KOD Kodiak Sciences Inc. | $5.5B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGON CG Oncology, Inc. | $5.5B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| MIRM Mirum Pharmaceuticals, Inc. | $5.4B | — (loss-making) | — (loss-making) | +37.92% (above 0%: growing) | n/m | −681.46% (below 0%: shrinking) | 82.78% | (24.14%) | Compare |
| ERAS Erasca, Inc. | $5.2B | — (loss-making) | — | — | n/m | −4.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| COGT Cogent Biosciences, Inc. | $5.1B | — (loss-making) | — (loss-making) | −69.41% (below 0%: shrinking) | n/m | −42.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $5.5B | — | — | +37.92% | — | −19.27% | 0.00% | 0.00% |
Immunovant, Inc. (IMVT) key facts
- Concern: Immunovant, Inc. reported a net loss of $505.6 million, or a loss of $2.77 per share, for fiscal 2026.
- Immunovant, Inc. (IMVT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, IMVT traded at $26.73, a market capitalization of $5.7 billion.
- Return on equity was −64.8% and debt-to-equity 0.00.